Wall Street researchers just used Claude to design a drug. The experiment has spawned a new investment thesis.
THE SO WHAT
Using Claude to design a drug and spinning an investment thesis off the experiment shows LLMs are now part of the drug discovery story investors underwrite. Biotech operators should assume diligence conversations will include your AI stack and data moats, not just wet lab assets.
READ THE SOURCE
MORE FROM THE WIRE
Applied AIPartnering with Blacksmith
If agents can write production-scale code, the new bottleneck is proving that code is safe, performant, and compliant at the same speed. Expect “agent-era CI/CD” vendors like Blacksmith to become a required layer in any serious agent deployment, not a nice-to-have devtool.
Applied AIHugging Face CEO warns that Netflix’s OpenAI hack documentary isn’t accurate
When a founder featured in a Netflix doc publicly calls it “full doomer mode,” you’re seeing the gap between narrative risk and operational reality. If your company touches AI or security, assume mainstream treatments will be dramatized—prepare a comms plan now for when your work is portrayed without nuance.
Applied AIEx-DeepMind researcher Thore Graepel launches London AI lab Metis Reasoning
A new lab built on the thesis that LLMs “cannot be trusted to reason” is a bet that post-LLM reasoning architectures will matter as much as scaling tokens. For product teams, this is a reminder to separate language fluency from decision quality—design systems where critical reasoning is modular and swappable.
Applied AIKen Griffin Says AI 'Almost Certainly' in a Bubble Right Now
When a major hedge fund operator calls AI “almost certainly” a bubble, he’s telegraphing volatility, not dismissing the tech. Founders and buyers should assume sharper repricing ahead—opt for contracts and cap tables that survive a sentiment swing rather than betting on today’s multiples.